注射用重组人TNK组织型纤溶酶原激活剂溶栓治疗急性ST段抬高型心肌梗死的疗效和安全性研究  

Study on the efficacy and safety of thrombolytic therapy with recombinant human TNK tissue-type plasminogen activator for injection for acute ST-segment elevation myocardial infarction

作　　者：张是善 ZHANG Shi-shan(Emergency Department,Youxi County General Hospital,Sanming 365100,China)

机构地区：[1]尤溪县总医院急诊科,365100

出　　处：《中国现代药物应用》2025年第5期63-66,共4页Chinese Journal of Modern Drug Application

摘　　要：目的分析采用注射用重组人TNK组织型纤溶酶原激活剂溶栓治疗急性ST段抬高型心肌梗死患者的临床疗效及安全性。方法113例急性ST段抬高型心肌梗死患者,按照治疗方式不同分为对照组(57例)和观察组(56例)。所有患者在诊断急性ST段抬高型心肌梗死后均给予常规治疗。对照组在常规治疗基础上给予尿激酶溶栓治疗,观察组在常规治疗基础上给予注射用重组人TNK组织型纤溶酶原激活剂溶栓治疗。对比两组患者临床再通率、并发症发生情况、二次心肌梗死发生情况。结果观察组临床再通率94.64%高于对照组的82.46%(P<0.05)。观察组并发症发生率7.14%低于对照组的21.05%(P<0.05)。观察组二次心肌梗死发生率5.36%低于对照组的19.30%(P<0.05)。结论急性ST段抬高型心肌梗死患者行注射用重组人TNK组织型纤溶酶原激活剂溶栓优势明显,可以有效地改善患者病情,及时促使血管再通,同时该治疗方式安全性良好,降低了患者出血风险,减少副作用,值得临床推广。Objective To analyze the clinical efficacy and safety of thrombolytic therapy with recombinant human TNK tissue-type plasminogen activator for injection in patients with acute ST-segment elevation myocardial infarction.Methods 113 patients with acute ST-segment elevation myocardial infarction as the research sample,and were divided into control group(57 cases)and observation group(56 cases)according different treatment methods.All patients were given conventional treatment after diagnosis of acute ST-segment elevation myocardial infarction.On this basis,the control group received thrombolytic therapy with urokinase,while the observation group received thrombolytic therapy with recombinant human TNK tissue-type plasminogen activator for injection.The clinical recanalization rate,incidence of complications,and occurrence of secondary myocardial infarction of the two groups were compared.Results The clinical recanalization rate of 94.64%in the observation group was higher than 82.46%in the control group(P<0.05).The complication rate of 7.14%in the observation group was lower than 21.05%in the control group(P<0.05).The incidence of secondary myocardial infarction of 5.36%in the observation group was lower than 21.05%in the control group(P<0.05).Conclusion The thrombolytic therapy with recombinant human TNK tissue-type plasminogen activator for injection has obvious advantages in patients with acute ST-segment elevation myocardial infarction,which can effectively improve the patient's condition and the vascular recanalization rate.Meanwhile,this treatment method has good safety,and can reduce the risk of bleeding and side effects of patients,and is worthy of clinical promotion.

关 键 词：注射用重组人TNK组织型纤溶酶原激活剂 溶栓 心肌梗死 

分 类 号：R54[医药卫生—心血管疾病]